Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]
Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.
Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]